Separately, Numis Securities restated a buy rating and issued a GBX 140 ($1.83) price objective on shares of Circassia Pharmaceuticals in a report on Thursday, September 27th.
Shares of CIR opened at GBX 75.90 ($0.99) on Wednesday.
Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally.
Further Reading: How to Invest in Growth Stocks
Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.